van den Heerik, Anne Sophie V M https://orcid.org/0000-0001-6403-0143
Horeweg, Nanda https://orcid.org/0000-0002-8581-4753
de Boer, Stephanie M
Bosse, Tjalling
Creutzberg, Carien L
Clinical trials referenced in this document:
Documents that mention this clinical trial
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy
https://doi.org/10.1136/ijgc-2020-001822
Management of nodal recurrences of endometrial cancer with IMRT
https://doi.org/10.1016/j.ygyno.2015.07.096
ESMO–ESGO–ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up
https://doi.org/10.1016/j.radonc.2015.11.013
Documents that mention this clinical trial
Molecular typing guiding treatment and prognosis of endometrial cancer
https://doi.org/10.1016/j.gocm.2023.01.011
Adjuvant chemotherapy and radiation for patients with high-risk stage I endometrial cancer treated with curative intent surgery: impact on recurrence and survival
https://doi.org/10.1136/ijgc-2021-003087
The time is now to start molecular subtyping high-intermediate and high-risk endometrial cancers
https://doi.org/10.1136/ijgc-2022-003709
Advances in the management of endometrial cancer
https://doi.org/10.1136/bmj-2024-080978
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy
https://doi.org/10.1136/ijgc-2020-001822
Role of adjuvant chemotherapy in patients with FIGO stage IB grade 3 endometrial endometrioid adenocarcinoma treated with surgery and post-operative radiotherapy
https://doi.org/10.1136/ijgc-2021-002380
Biomarker-driven therapy in endometrial cancer
https://doi.org/10.1136/ijgc-2022-003676
PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer
https://doi.org/10.1136/ijgc-2020-001929
Documents that mention this clinical trial
Outcomes and endpoints of relevance in gynecologic cancer clinical trials
https://doi.org/10.1136/ijgc-2022-003727
Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study
https://doi.org/10.1136/ijgc-2021-002881
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy
https://doi.org/10.1136/ijgc-2020-001822
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
https://doi.org/10.1200/jco.22.02152
Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775
https://doi.org/10.1136/jitc-2025-013713
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Documents that mention this clinical trial
Best original research presented at the 25th European Congress on Gynaecological Oncology: best of ESGO 2024
https://doi.org/10.1136/ijgc-2024-005844
Genome tumor profiling in endometrial cancer and clinical relevance in endometrial cancer management: a retrospective single-center experience
https://doi.org/10.1136/ijgc-2022-003997
Molecular typing guiding treatment and prognosis of endometrial cancer
https://doi.org/10.1016/j.gocm.2023.01.011
Real-world patient characteristics and survival outcomes in patients with advanced or recurrent endometrial cancer in England: a retrospective, population-based study
https://doi.org/10.1136/bmjopen-2023-083540
Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study
https://doi.org/10.1136/ijgc-2021-002881
Advances in the management of endometrial cancer
https://doi.org/10.1136/bmj-2024-080978
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy
https://doi.org/10.1136/ijgc-2020-001822
Neoadjuvant immunotherapy of locoregionally advanced solid tumors
https://doi.org/10.1136/jitc-2022-005036
323 ENGOT-en9/LEAP-001: a phase 3 study of first-line pembrolizumab plus lenvatinib compared with chemotherapy in advanced or recurrent endometrial cancer
https://doi.org/10.1136/ijgc-2020-igcs.277
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
https://doi.org/10.1136/ijgc-2021-003017
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Biomarker-driven therapy in endometrial cancer
https://doi.org/10.1136/ijgc-2022-003676
#88 Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: primary results of the phase 3 ENGOT-en9/LEAP-001 study
https://doi.org/10.1136/ijgc-2024-esgo.1115
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial
https://doi.org/10.1200/jco-24-01326
Documents that mention this clinical trial
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair–proficient (MMR-P) recurrent or persistent endometrial cancer (EC).
https://doi.org/10.1200/jco.2023.41.16_suppl.tps5628
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy
https://doi.org/10.1136/ijgc-2020-001822
Biomarker-driven therapy in endometrial cancer
https://doi.org/10.1136/ijgc-2022-003676
Documents that mention this clinical trial
Molecular typing guiding treatment and prognosis of endometrial cancer
https://doi.org/10.1016/j.gocm.2023.01.011
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy
https://doi.org/10.1136/ijgc-2020-001822
Funding for this research was provided by:
KWF Kankerbestrijding (12376)
KWF Kankerbestrijding (UL2011-5336)
This article is maintained by: Elsevier
Article Title: Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy
Journal Title: International Journal of Gynecological Cancer
CrossRef DOI link to publisher maintained version: https://doi.org/10.1136/ijgc-2020-001822
Content Type: article
Copyright: Copyright This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.